Sharps Technology Inc. Files S-1 with SEC

TL;DR

Sharps Tech filed an S-1, check financials for potential moves.

AI Summary

Sharps Technology Inc. filed an S-1 form on January 10, 2025, detailing its business operations and financial status. The company, incorporated in Nevada with its principal executive offices in Melville, NY, operates in the Surgical & Medical Instruments & Apparatus industry. The filing includes financial data for periods ending September 30, 2024, and December 31, 2023, and 2022, indicating ongoing financial reporting and potential future public offerings.

Why It Matters

This S-1 filing provides crucial insights into Sharps Technology Inc.'s financial health and business strategy, which is essential for investors and market analysts to assess the company's potential and risks.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant corporate actions like IPOs or secondary offerings, which carry inherent market risks.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Latest interim financial reporting period covered in the filing.)
• 2023-12-31 — Fiscal Year End (End date of the most recent full fiscal year reported.)
• 333-284237 — SEC File Number (Unique identifier for the company's SEC filings.)

Key Players & Entities

• Sharps Technology Inc. (company) — Filer of the S-1 document.
• 0001493152-25-001790 (filing_id) — Accession number for the S-1 filing.
• 20250110 (date) — Date the S-1 filing was submitted.
• Melville, NY (location) — Location of Sharps Technology Inc.'s business and mailing address.
• 3841 (sic_code) — Standard Industrial Classification code for Surgical & Medical Instruments & Apparatus.

FAQ

Key Financial Figures

• $2.787 — is exercisable at an exercise price of $2.787 per share (125% of the assumed public o
• $2.23 — at an assumed public offering price of $2.23 per Unit, equal to the closing price of
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
• $0.0001 — rant included in the Pre-Funded Unit is $0.0001 per share. The Pre-Funded Warrants will
• $100,000 — ts of its legal counsel in an amount of $100,000. See " Underwriting " beginning on page
• $ — icated, all references to "dollars," "US$," or "
  quot; in this prospectus are to Unit
• $4,174,658 — es and to repay the principal amount of $4,174,658 in outstanding senior notes of the Comp

Filing Documents

• forms-1.htm (S-1) — 2892KB
• ex1-1.htm (EX-1.1) — 328KB
• ex5-1.htm (EX-5.1) — 21KB
• ex10-36.htm (EX-10.36) — 183KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 6KB
• ex107.htm (EX-FILING FEES) — 33KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• form10-k_001.jpg (GRAPHIC) — 11KB
• form10-k_002.jpg (GRAPHIC) — 9KB
• form10-k_004.jpg (GRAPHIC) — 4KB
• form10-k_005.jpg (GRAPHIC) — 4KB
• forms-1_002.jpg (GRAPHIC) — 6KB
• ex5-1_001.jpg (GRAPHIC) — 656KB
• ex23-1_001.jpg (GRAPHIC) — 28KB
• ex23-2_001.jpg (GRAPHIC) — 17KB
• ex23-2_002.jpg (GRAPHIC) — 9KB
• 0001493152-25-001790.txt ( ) — 12864KB
• stss-20240930.xsd (EX-101.SCH) — 64KB
• stss-20240930_cal.xml (EX-101.CAL) — 81KB
• stss-20240930_def.xml (EX-101.DEF) — 349KB
• stss-20240930_lab.xml (EX-101.LAB) — 495KB
• stss-20240930_pre.xml (EX-101.PRE) — 423KB
• forms-1_htm.xml (XML) — 1925KB

RISK FACTORS

RISK FACTORS 7 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 15

USE OF PROCEEDS

USE OF PROCEEDS 15 DIVIDEND POLICY 16 CAPITALIZATION 16

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 17

BUSINESS

BUSINESS 24 MANAGEMENT 29

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 32 MARKET PRICE OF AND DIVIDENDS ON THE COMPANY'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 36 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 40 PRIVATE PLACEMENT OF SHARES OF COMMON STOCK,AND WARRANTS 41

UNDERWRITING

UNDERWRITING 42 LEGAL MATTERS 44 EXPERTS 44 WHERE YOU CAN FIND ADDITIONAL INFORMATION 44 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under "Where You Can Find More Information." You should carefully read this prospectus as well as additional information described under "Information Incorporated By Reference," before deciding to invest in our securities. Neither we nor Aegis have authorized anyone to provide you with information different from or inconsistent with the information contained in or incorporated by reference in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information appearing in this prospectus and the documents incorporated by reference in this prospectus is accurate only as of the date of those respective documents, regardless of the time of delivery of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable. While we believe our internal company research is reliable and the definitions of our market and industry are appropriate, neither this research nor these definitions have been verified by any independent source. We furt

View Full Filing

View this S-1 filing on SEC EDGAR